Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton, Dickinson and Co.

Becton, Dickinson and Company is a global healthcare company specializing in medical supplies, devices, and diagnostic products. BDX saw solid growth in Q3 driven by strong demand for pharmacy automation systems and medical devices. The company raised its revenue guidance for FY23 and expects continued profitability improvement in the near future.

Becton, Dickinson Stock Is A Hold, Here's Why

Becton Dickinson beat Wall Street estimates for third-quarter profit on Thursday, helped by strong demand for its drug delivery devices and surgical equipment.

Becton Dickinson beats quarterly profit estimates on strong medical device sales

Shares of Becton Dickinson rose to their highest level since 2020 after the FDA gave 501(k) clearance to Becton Dickinson's updated BD Alaris Infusion System.

Becton Dickinson Shares Jump After FDA Decision on Its Infusion System

Shares of Becton Dickinson hit an all-time high on Monday and were last up 6.1% after the medical device maker received U.S. Food and Drug Administration clearance late on Friday for the market return of its drug infusion system.

Becton Dickinson shares hit record high after US FDA clears return of drug infusion system

The company filed a 501(k) resubmission for its new BD Alaris Infusion System two years ago. The company said it will begin immediately distributing the new Alaris Infusion System, and will remediate older versions of the device.

Why Shares of Becton, Dickinson Rose Monday

Becton, Dickinson and Company has seen another year of relative stagnation. Following the spinoff of the Diabetes Care unit, sales and earnings have taken a small setback. Valuations remain full at around 20 times adjusted earnings amidst some leverage still being apparent and with structural growth hard to come by.

Becton, Dickinson and Company: Still Not Very Healthy

I expect Becton, Dickinson and Company to beat 2H23 estimates due to reduced expectations and margin improvements. BDX's management has made progress in SKU rationalizations, workforce reduction, and enhancing the company's structural margin profile. The stable operating environment, procedure volume recovery, and hospital capital spending appetite support revenue growth for BDX.

Becton, Dickinson: Business Should Beat H2 2023 Expectations

Becton Dickinson stock (NYSE: BDX) has seen a 7% fall this year, faring better than the broader S&P500 index, down 17%.

Is There More Room For Growth In Becton Dickinson Stock?

Becton Dickinson & Co. stock BDX, -0.55% slid 1.3% in premarket trade Thursday, after the medical tech and diagnostics company beat estimates for its fiscal fourth quarter but offered guidance that lagged. The Franklin Lakes, N.J.

Becton Dickinson stock down 1.3% premarket as Q4 earnings beat tempered by soft fiscal 2023 guidance

Becton Dickinson & Co. BDX, -0.55% said Thursday its board has approved a 4.6% increase in its quarterly dividend to 91 cents a share. The medical tech and diagnostics company said the new dividend is payable Dec. 30 to shareholders of record as of Dec. 9.

Becton Dickinson raises quarterly dividend by 4.6% to 91 cents a share

Eli Lilly

There is more to the comparison, and in the sections below, we discuss why we believe BDX stock will offer better returns than LLY stock in the next three years.

This Healthcare Company Is Likely To Offer Better Returns Over Eli Lilly Stock

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Becton Dickinson (BDX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2022 Results - Earnings Call Transcript

Becton Dickinson and Co BDX reported Q1 FY22 revenues of $4.9 billion, down 6% Y/Y (-5.9% on a currency-neutral basis), better than the consensus of $4.76 billion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Becton Dickinson Q1 Earnings Top Estimates, Raises FY22 Guidance On Higher COVID-19 Related Sales

Becton Dickinson (BDX) delivered earnings and revenue surprises of 27.27% and 4.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates

Becton, Dickinson and Company (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Becton, Dickinson and Company (BDX) Ahead of Earnings?

Becton, Dickinson and Co (NYSE: BDX) has acquired Cytognos, a unit of Vitro SA, a Spanish diagnostics company that develops, produces, and sells fully integrated reagents, hardware, and software platforms. Deal terms were not disclosed.

Becton Dickinson Strengthens Post-Treatment Monitoring For Blood Cancers With Cytognos Acquisition

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Becton Dickinson (BDX)

Beckton, Dickinson and Company is a Profitable Dividend Aristocrat that generates tons of cash.

Becton, Dickinson And Company: Stable, Profitable, And Offering At-Home COVID-19 Testing

BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.

BD (BDX) Partners With Retailers for At-Home COVID-19 Test

Becton Dickinson & Co. BDX, +0.90% said Monday that the spinoff of its diabetes care business will be named "embecta." The previously announced spinoff, into an independent publicly traded company, is expected to be completed in the second quarter of 2022.

Becton Dickinson to name diabetes care spinoff 'embecta'

Shares of Becton, Dickinson and Co. ( BDX , Financial) reported earnings results earlier this month that came in above Wall Street analysts' estimates. Covid-19 remains a tailwind to the company's business, but the core segments also performed well.

Becton, Dickinson & Co. Is Trading at a Discount

QIAGEN

Qiagen N.V. (NYSE: QGEN) settled with Becton Dickinson & Co (NYSE: BDX) a patent infringement lawsuit related to Qiagen's NeuMoDx 96 and NeuMoDx 288 clinical PCR systems.

Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M

Becton, Dickinson and Company's (BDX) CEO Tom Polen on Q4 2021 Results - Earnings Call Transcript

Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.58% and 4.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A Stock (BDXA)